Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Here's Why Unity Biotechnology Is Getting Crushed Today

TheMotleyFool

0 0

Here's Why Unity Biotechnology Is Getting Crushed TodayPhoto, wide shot, wide-angle lens, Clinical research organization, sunset photo at golden hour, photo by Peter Lik: https://img.midjourneyapi.xyz/temp/02f7778c-d723-4fb3-bdef-fabb7e5fc9c8.png

Shares of Unity Biotechnology (NASDAQ: UBX) fell over 63% today after the company announced disappointing results from a clinical trial involving its lead drug candidate, UBX0101.

At the 12-week mark of a phase 2 study, the pipeline asset failed to meet its primary endpoint in alleviating moderate to severe painful osteoarthritis (OA) of the knee. In fact, there were no statistically significant differences between any dose of UBX0101 and placebo.

As of 1:22 p.m. EDT, the small-cap stock had settled to a 61.3% loss.

Source Fool.com

Like: 0

UBX

Teilen